A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
Latest Information Update: 06 Sep 2026
At a glance
- Drugs Garsorasib (Primary) ; Ifebemtinib (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors InxMed
Most Recent Events
- 28 Aug 2026 According to an InxMed media release, results from this trial have been published online in The Lancet Oncology.
- 28 Aug 2026 Results presented in the InxMed media release.
- 25 Mar 2026 Status changed from recruiting to active, no longer recruiting.